Trial Profile
A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Cancer; Neurofibromatoses; Neurofibromatosis 1; Plexiform neurofibroma
- Focus Adverse reactions; Pharmacogenomic; Pharmacokinetics; Therapeutic Use
- 01 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.(NCT00652990).
- 01 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.(NCT00652990).
- 10 May 2012 Actual patient number is 18 according to ClinicalTrials.gov.(NCT00652990).